X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
yn968d1 (35) 35
apatinib (26) 26
index medicus (22) 22
inhibitor (20) 20
humans (17) 17
chemotherapy (13) 13
pyridines - therapeutic use (13) 13
angiogenesis (12) 12
pharmacology & pharmacy (12) 12
cancer (9) 9
female (9) 9
male (9) 9
pharmacokinetics (9) 9
colorectal cancer (8) 8
middle aged (8) 8
antineoplastic agents - therapeutic use (7) 7
care and treatment (7) 7
oncology (7) 7
case report (6) 6
cell biology (6) 6
double-blind (6) 6
drug therapy (6) 6
endothelial growth-factor (6) 6
metastasis (6) 6
pyridines - pharmacokinetics (6) 6
pyridines - pharmacology (6) 6
targeted therapy (6) 6
treatment outcome (6) 6
tumors (6) 6
tyrosine kinase (6) 6
vegf (6) 6
5700 (5) 5
animals (5) 5
cancer therapies (5) 5
gastric-cancer (5) 5
growth (5) 5
medicine, general & internal (5) 5
multicenter phase-ii (5) 5
patient outcomes (5) 5
patients (5) 5
phase-ii (5) 5
protein kinase inhibitors - therapeutic use (5) 5
vascular endothelial growth factor (5) 5
vascular endothelial growth factor receptor-2 - antagonists & inhibitors (5) 5
abridged index medicus (4) 4
adenocarcinoma (4) 4
administration, oral (4) 4
adult (4) 4
aged (4) 4
angiogenesis inhibitors - therapeutic use (4) 4
apoptosis (4) 4
breast-cancer (4) 4
docetaxel (4) 4
drugs (4) 4
efficacy (4) 4
enzyme inhibitors (4) 4
expression (4) 4
health aspects (4) 4
hypertension (4) 4
lung neoplasms - drug therapy (4) 4
neoplasms - drug therapy (4) 4
research (4) 4
sarcoma (4) 4
therapy (4) 4
angiogenesis inhibitor (3) 3
angiogenesis inhibitors - pharmacokinetics (3) 3
anti-angiogenesis (3) 3
breast cancer (3) 3
cell cycle (3) 3
chemotherapy resistance (3) 3
clinical case report (3) 3
clinical trials (3) 3
colon cancer (3) 3
disease-free survival (3) 3
in-vitro (3) 3
kinases (3) 3
lung cancer (3) 3
mechanisms (3) 3
medical prognosis (3) 3
medicine, research & experimental (3) 3
neoplasms - pathology (3) 3
pharmacology (3) 3
placebo (3) 3
proteins (3) 3
pyridines - administration & dosage (3) 3
pyridines - adverse effects (3) 3
soft-tissue sarcoma (3) 3
stomach cancer (3) 3
stomach neoplasms - drug therapy (3) 3
stomach neoplasms - pathology (3) 3
survival (3) 3
tyrosine (3) 3
vascular endothelial growth factor receptors (3) 3
vegfr-2 (3) 3
young adult (3) 3
adolescent (2) 2
advanced gastric-cancer (2) 2
angiogenesis inhibitors (2) 2
angiogenesis inhibitors - adverse effects (2) 2
anticancer properties (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cell Cycle, ISSN 1538-4101, 05/2018, Volume 17, Issue 10, pp. 1235 - 1244
Apatinib is a novel tyrosine kinase inhibitor that targets VEGFR2 signal and exhibits potent anti-tumor effects in human cancers. In this study, we aim to... 
Apatinib | VEGFR2 signal | cell cycle | Cervical cancer | cellular proliferation | YN968D1 | STATISTICS | VEGF | CIN | EXPRESSION | CELL BIOLOGY
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 11/2018, Volume 19, Issue 6, pp. e831 - e842
Apatinib is an oral multi-tyrosine kinase inhibitor that has been effective in treating many solid tumors. This phase II clinical trial evaluated the efficacy... 
Anti-angiogenesis | NSCLC | Targeted therapy | VEGFR-2 | SIGNALING PATHWAYS | ANGIOGENESIS | VEGF | PLATINUM | DOCETAXEL | YN968D1 | ONCOLOGY | GEFITINIB-RESISTANCE | RECEPTOR-2
Journal Article
Medicine (United States), ISSN 0025-7974, 11/2017, Volume 96, Issue 47, pp. e8725 - e8725
Rationale: Malignant ascites (MA) is one of the poor prognostic factors for advanced pancreatic cancer and can bring about serious symptoms. The improvement of... 
pancreatic cancer | gemcitabine | malignant ascites | apatinib | PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | PLACEBO | YN968D1 | BEVACIZUMAB | ADENOCARCINOMA | DOUBLE-BLIND | Index Medicus | Abridged Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 38, pp. 64471 - 64480
Purpose: This study was conducted to review the efficacy and safety of Apatinib in stage IV sarcoma patients who failed previous chemotherapy. Materials and... 
Apatinib | Efficacy | Sarcoma | Clinical benefit response | Progression free survival | sarcoma | clinical benefit response | TYROSINE KINASE | TUMORS | efficacy | progression free survival | CHEMOTHERAPY | CELL BIOLOGY | PHASE-II TRIAL | YN968D1 | GASTRIC-CANCER | CANCER STATISTICS | INHIBITOR | SOFT-TISSUE SARCOMA | ENDOTHELIAL GROWTH-FACTOR
Journal Article
by Jiang, Q and Zhang, NL and Ma, DY and Tan, BX and Hu, X and Fang, XD
MEDICINE, ISSN 0025-7974, 06/2019, Volume 98, Issue 26, pp. e16065 - e16065
Background: Apatinib is an oral small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). Some clinical... 
MULTICENTER | nonsquamous NSCLC | ANGIOGENESIS | apatinib | VEGF | second or above line treatment | OPEN-LABEL | CHEMOTHERAPY | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | MEDICINE, GENERAL & INTERNAL | YN968D1 | docetaxel | MUTATIONS | ERLOTINIB | Patient outcomes | Docetaxel | Dosage and administration | Drug therapy, Combination | Lung cancer, Non-small cell | Drug therapy | Methods
Journal Article
Medicine, ISSN 0025-7974, 12/2018, Volume 97, Issue 50, pp. e13635 - e13635
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 02/2018, Volume 16, Issue 1, pp. 47 - 47
Journal Article
by He, SL and Shen, J and Hu, NH and Xu, XD and Li, J
ONCOLOGY LETTERS, ISSN 1792-1074, 02/2017, Volume 13, Issue 2, pp. 587 - 592
Dickkopf-related protein 4 (DKK4) is a target of the beta-catenin/transcription factor 4 complex in colorectal cancer. Previous research has demonstrated that... 
colorectal cancer | MECHANISMS | DICKKOPF-4 | STRATEGIES | COLON-CANCER | chemotherapy resistance | 5-FLUOROURACIL | YN968D1 | ONCOLOGY | GROWTH | dickkopf-related protein 4,5-fluorouracil | INHIBITOR | EXPRESSION
Journal Article
Journal Article
Iranian Journal of Basic Medical Sciences, ISSN 2008-3866, 09/2017, Volume 20, Issue 9, pp. 990 - 995
Objective(s): Apatinib recently has been used to treat patients with gastric cancer, but the function of apatinib in colon cancer remains unclear. This study... 
Apatinib | mTOR | Colon cancer | Autophagy | Migration | Apoptosis | MEDICINE, RESEARCH & EXPERIMENTAL | TYROSINE KINASE | YN968D1 | PHARMACOKINETICS | METABOLISM | GASTRIC-CANCER | COLORECTAL-CANCER | GROWTH | DISEASE | PHARMACOLOGY & PHARMACY | INHIBITOR | PROTEINS | Colorectal cancer | Cell cycle | Original
Journal Article
International Journal of Nanomedicine, ISSN 1176-9114, 03/2017, Volume 12, pp. 1941 - 1958
Journal Article